Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum

George Elgart, William Sheremata, Yeon Ahn

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Recombinant human interferon beta-1b has been recently approved for the treatment of multiple sclerosis. A significant proportion of patients treated with this medication experienced cutaneous reactions. Objective: We describe the clinical and histologic features of cutaneous reactions to recombinant human interferon beta-1b. Methods: Consecutive patients with cutaneous reactions to recombinant interferon beta-1b were evaluated clinically and by biopsy. Results: Clinical lesions varied from subtle uninflamed sclerotic dermal plaques to erythematous plaques to cutaneous ulcers at injection sites. The nonsclerotic lesions were frequently painful. The firm plaques showed fibrosis histologically, whereas nonsclerotic inflammatory lesions demonstrated a consistent pattern of vascular thrombosis. Hematologic evaluation demonstrated platelet activation in most patients with inflammatory lesions, a feature also noted before interferon treatment in some patients. Conclusion: Therapy with recombinant interferon beta-1b is associated with a spectrum of cutaneous reactions and vascular thrombosis.

Original languageEnglish
Pages (from-to)553-558
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume37
Issue number4
DOIs
StatePublished - Oct 28 1997

Fingerprint

Skin
Blood Vessels
Thrombosis
Skin Ulcer
Platelet Activation
Interferons
Multiple Sclerosis
Fibrosis
Therapeutics
Interferon beta-1b
Biopsy
Injections

ASJC Scopus subject areas

  • Dermatology

Cite this

Cutaneous reactions to recombinant human interferon beta-1b : The clinical and histologic spectrum. / Elgart, George; Sheremata, William; Ahn, Yeon.

In: Journal of the American Academy of Dermatology, Vol. 37, No. 4, 28.10.1997, p. 553-558.

Research output: Contribution to journalArticle

@article{b3f4a1b46e124d3088b35ae196ee63e7,
title = "Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum",
abstract = "Background: Recombinant human interferon beta-1b has been recently approved for the treatment of multiple sclerosis. A significant proportion of patients treated with this medication experienced cutaneous reactions. Objective: We describe the clinical and histologic features of cutaneous reactions to recombinant human interferon beta-1b. Methods: Consecutive patients with cutaneous reactions to recombinant interferon beta-1b were evaluated clinically and by biopsy. Results: Clinical lesions varied from subtle uninflamed sclerotic dermal plaques to erythematous plaques to cutaneous ulcers at injection sites. The nonsclerotic lesions were frequently painful. The firm plaques showed fibrosis histologically, whereas nonsclerotic inflammatory lesions demonstrated a consistent pattern of vascular thrombosis. Hematologic evaluation demonstrated platelet activation in most patients with inflammatory lesions, a feature also noted before interferon treatment in some patients. Conclusion: Therapy with recombinant interferon beta-1b is associated with a spectrum of cutaneous reactions and vascular thrombosis.",
author = "George Elgart and William Sheremata and Yeon Ahn",
year = "1997",
month = "10",
day = "28",
doi = "10.1016/S0190-9622(97)70170-1",
language = "English",
volume = "37",
pages = "553--558",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Cutaneous reactions to recombinant human interferon beta-1b

T2 - The clinical and histologic spectrum

AU - Elgart, George

AU - Sheremata, William

AU - Ahn, Yeon

PY - 1997/10/28

Y1 - 1997/10/28

N2 - Background: Recombinant human interferon beta-1b has been recently approved for the treatment of multiple sclerosis. A significant proportion of patients treated with this medication experienced cutaneous reactions. Objective: We describe the clinical and histologic features of cutaneous reactions to recombinant human interferon beta-1b. Methods: Consecutive patients with cutaneous reactions to recombinant interferon beta-1b were evaluated clinically and by biopsy. Results: Clinical lesions varied from subtle uninflamed sclerotic dermal plaques to erythematous plaques to cutaneous ulcers at injection sites. The nonsclerotic lesions were frequently painful. The firm plaques showed fibrosis histologically, whereas nonsclerotic inflammatory lesions demonstrated a consistent pattern of vascular thrombosis. Hematologic evaluation demonstrated platelet activation in most patients with inflammatory lesions, a feature also noted before interferon treatment in some patients. Conclusion: Therapy with recombinant interferon beta-1b is associated with a spectrum of cutaneous reactions and vascular thrombosis.

AB - Background: Recombinant human interferon beta-1b has been recently approved for the treatment of multiple sclerosis. A significant proportion of patients treated with this medication experienced cutaneous reactions. Objective: We describe the clinical and histologic features of cutaneous reactions to recombinant human interferon beta-1b. Methods: Consecutive patients with cutaneous reactions to recombinant interferon beta-1b were evaluated clinically and by biopsy. Results: Clinical lesions varied from subtle uninflamed sclerotic dermal plaques to erythematous plaques to cutaneous ulcers at injection sites. The nonsclerotic lesions were frequently painful. The firm plaques showed fibrosis histologically, whereas nonsclerotic inflammatory lesions demonstrated a consistent pattern of vascular thrombosis. Hematologic evaluation demonstrated platelet activation in most patients with inflammatory lesions, a feature also noted before interferon treatment in some patients. Conclusion: Therapy with recombinant interferon beta-1b is associated with a spectrum of cutaneous reactions and vascular thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=0030793925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030793925&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(97)70170-1

DO - 10.1016/S0190-9622(97)70170-1

M3 - Article

C2 - 9344192

AN - SCOPUS:0030793925

VL - 37

SP - 553

EP - 558

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -